JP2025515996A5 - - Google Patents

Info

Publication number
JP2025515996A5
JP2025515996A5 JP2024560406A JP2024560406A JP2025515996A5 JP 2025515996 A5 JP2025515996 A5 JP 2025515996A5 JP 2024560406 A JP2024560406 A JP 2024560406A JP 2024560406 A JP2024560406 A JP 2024560406A JP 2025515996 A5 JP2025515996 A5 JP 2025515996A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
base sequence
strand comprises
acid base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515996A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065812 external-priority patent/WO2023201362A2/en
Publication of JP2025515996A publication Critical patent/JP2025515996A/ja
Publication of JP2025515996A5 publication Critical patent/JP2025515996A5/ja
Pending legal-status Critical Current

Links

JP2024560406A 2022-04-14 2023-04-14 酵素補充療法を用いたFN3ドメイン-siRNAコンジュゲート Pending JP2025515996A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263330797P 2022-04-14 2022-04-14
US63/330,797 2022-04-14
PCT/US2023/065812 WO2023201362A2 (en) 2022-04-14 2023-04-14 Fn3 domain-sirna conjugates with enzyme replacement therapy

Publications (2)

Publication Number Publication Date
JP2025515996A JP2025515996A (ja) 2025-05-23
JP2025515996A5 true JP2025515996A5 (cg-RX-API-DMAC7.html) 2026-04-20

Family

ID=88330423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560406A Pending JP2025515996A (ja) 2022-04-14 2023-04-14 酵素補充療法を用いたFN3ドメイン-siRNAコンジュゲート

Country Status (9)

Country Link
US (1) US20240043844A1 (cg-RX-API-DMAC7.html)
EP (1) EP4507702A2 (cg-RX-API-DMAC7.html)
JP (1) JP2025515996A (cg-RX-API-DMAC7.html)
KR (1) KR20250024745A (cg-RX-API-DMAC7.html)
CN (1) CN119604311A (cg-RX-API-DMAC7.html)
AU (1) AU2023252976A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248570A1 (cg-RX-API-DMAC7.html)
IL (1) IL316071A (cg-RX-API-DMAC7.html)
WO (1) WO2023201362A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Cd71に結合するフィブロネクチンiii型ドメイン
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
WO2025231388A1 (en) * 2024-05-03 2025-11-06 Aro Biotherapeutics Company Methods and compositions for treating pompe disease
WO2025245474A1 (en) * 2024-05-23 2025-11-27 Aro Biotherapeutics Company Formulations comprising fn3-sirna conjugates and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072057A2 (en) * 2004-01-30 2005-08-11 Quark Biotech, Inc. Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
CN102076713B (zh) * 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
US11781138B2 (en) * 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
US20230330246A1 (en) * 2020-05-05 2023-10-19 Avidity Biosciences, Inc. Compositions and methods of treating pompe disease
KR20240031947A (ko) * 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2024514266A5 (cg-RX-API-DMAC7.html)
Lang et al. Coronavirus hemagglutinin-esterase and spike proteins coevolve for functional balance and optimal virion avidity
Chen et al. Gene transfer with poly-melittin peptides
Benzing et al. Nephrocystin interacts with Pyk2, p130Cas, and tensin and triggers phosphorylation of Pyk2
Fujii et al. Crystal structure of an IRF‐DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences
Wang et al. Structural basis for receptor specificity of influenza B virus hemagglutinin
Rasmussen et al. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog
CN109803977A (zh) 核酸产品及其施用方法
Murakami et al. The two α subunits of Escherichia coli RNA polymerase are asymmetrically arranged and contact different halves of the DNA upstream element
Manjunath et al. Mammalian proteome expansion by stop codon readthrough
JP2020508685A5 (cg-RX-API-DMAC7.html)
EP4428232A1 (en) Isolated cas13 protein and use thereof
ES2804594T3 (es) Reticuladores químicos
Daum et al. Self-assembly of the general membrane-remodeling protein PVAP into sevenfold virus-associated pyramids
Miyake et al. Origin and diversity of alginate lyases of families PL-5 and-7 in Sphingomonas sp. strain A1
JP2010516758A5 (cg-RX-API-DMAC7.html)
Fuqua et al. Bulk production of the antiviral lectin griffithsin
CA2825023A1 (en) Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
CN113150084B (zh) 一种纳米化的冠状病毒抗原及其应用
Tomanin et al. Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases
Kormos et al. Binding site analysis of cellulose binding domain CBDN1 from endoglucanse C of Cellulomonas fimi by site-directed mutagenesis
Sikriwal et al. An insertion in loop L7 of human eosinophil‐derived neurotoxin is crucial for its antiviral activity
Antcheva et al. Effects of positively selected sequence variations in human and Macaca fascicularis β-defensins 2 on antimicrobial activity
Xiang et al. Targeted delivery of large fusion protein into hippocampal neurons by systemic administration
Abe et al. Peptide-mediated gene and protein delivery systems to plant mitochondria for modifying mitochondrial functions